Sandip M Kanse Selected Research

Factor VII (Proconvertin)

1/2020	Protease activated receptors (PAR)-1 and -2 mediate cellular effects of factor VII activating protease (FSAP).
1/2020	Factor VII Activating Protease Expression in Human Platelets and Accumulation in Symptomatic Carotid Plaque.
10/2019	Fluorescent activity-based probe for the selective detection of Factor VII activating protease (FSAP) in human plasma.
10/2017	Factor VII activating protease (FSAP) regulates the expression of inflammatory genes in vascular smooth muscle and endothelial cells.
1/2017	Factor VII activating protease (FSAP) influences vascular remodeling in the mouse hind limb ischemia model.
9/2016	Transforming Growth Factor-β (TGF-β) Inhibits the Expression of Factor VII-activating Protease (FSAP) in Hepatocytes.
1/2016	Factor seven activating protease (FSAP) predicts response to intravenous thrombolysis in acute ischemic stroke.
4/2015	Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP).
6/2014	Factor VII activating protease (FSAP): a novel protective factor in liver fibrosis.
10/2013	Regulation of monocyte/macrophage function by factor VII activating protease (FSAP).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sandip M Kanse Research Topics

Disease

8	Inflammation (Inflammations) 01/2022 - 06/2003
6	Thrombosis (Thrombus) 01/2020 - 12/2014
6	Stroke (Strokes) 01/2020 - 01/2011
6	Neointima 10/2017 - 12/2006
6	Liver Cirrhosis (Hepatic Cirrhosis) 09/2016 - 03/2009
3	Neoplasms (Cancer) 01/2021 - 01/2017
3	Atherosclerosis 01/2020 - 12/2004
3	Vascular Remodeling 01/2017 - 03/2013
3	Fibrosis (Cirrhosis) 06/2014 - 03/2009
2	Atherosclerotic Plaque (Atheroma) 01/2020 - 01/2008
2	Vascular System Injuries 10/2017 - 06/2003
2	Multiple Trauma (Multiple Injuries) 03/2012 - 02/2012
2	Wounds and Injuries (Trauma) 03/2012 - 02/2012
2	Stable Angina 01/2012 - 01/2008
2	Acute Coronary Syndrome 01/2012 - 01/2008
2	Myocardial Infarction 01/2012 - 11/2002
2	Vascular Diseases (Vascular Disease) 01/2011 - 12/2004
2	Cardiovascular Diseases (Cardiovascular Disease) 06/2009 - 12/2006
2	Infections 03/2009 - 06/2003
2	Carotid Stenosis (Carotid Artery Stenosis) 12/2006 - 04/2004
1	Thrombophilia 01/2022
1	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2021
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021
1	Hemorrhage 01/2020
1	Venous Thrombosis (Deep-Vein Thrombosis) 09/2019
1	Hemophilia A (Haemophilia) 12/2018
1	Infarction (Infarctions) 10/2017
1	Ischemia 01/2017
1	Genetic Predisposition to Disease (Genetic Predisposition) 02/2016
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2016
1	Ischemic Stroke 01/2016
1	Pulmonary Embolism 04/2015
1	Unstable Angina 01/2012
1	Acute-Phase Reaction 05/2009
1	Hepatitis C 03/2009
1	Chronic Hepatitis C 03/2009
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 07/2007

Drug/Important Bio-Agent (IBA)

26	Peptide Hydrolases (Proteases)FDA Link 01/2020 - 06/2003
23	Factor VII (Proconvertin)IBA 01/2020 - 04/2004
5	Becaplermin (PDGF-BB)FDA Link 05/2009 - 12/2006
4	Serine Proteases (Serine Protease)IBA 01/2022 - 04/2004
4	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2021 - 11/2002
3	Plasminogen Activators (Plasminogen Activator)IBA 01/2021 - 04/2004
3	Messenger RNA (mRNA)IBA 01/2012 - 01/2008
3	Proteins (Proteins, Gene)FDA Link 05/2009 - 01/2008
2	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2021 - 12/2018
2	Histones (Histone)IBA 01/2020 - 10/2019
2	Enzyme Precursors (Zymogens)IBA 01/2020 - 10/2019
2	LipidsIBA 01/2020 - 01/2008
2	Protein Isoforms (Isoforms)IBA 12/2018 - 02/2008
2	Matrix Metalloproteinases (MMPs)IBA 01/2016 - 01/2011
2	AntigensIBA 01/2016 - 01/2008
2	AnaphylatoxinsIBA 03/2012 - 02/2012
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022
1	Epithelial Sodium ChannelsIBA 01/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022
1	AnticoagulantsIBA 01/2022
1	VenomsIBA 01/2022
1	SodiumIBA 01/2022
1	Thrombin FDA Link 01/2022
1	VLDL LipoproteinsIBA 01/2021
1	Mitogen-Activated Protein KinasesIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Complement C3 (C3 Complement)IBA 09/2019
1	Proteinase-Activated ReceptorsIBA 12/2018
1	FibrinIBA 10/2018
1	SKP Cullin F-Box Protein LigasesIBA 01/2017
1	F-Box ProteinsIBA 01/2017
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2017
1	Metalloproteases (Metalloproteinases)IBA 01/2017
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2016
1	CollagenIBA 04/2015
1	Epinephrine (Adrenaline)FDA LinkGeneric 04/2015
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 12/2014
1	ferric chlorideIBA 12/2014
1	ProteomeIBA 06/2014
1	Collagen Type I (Type I Collagen)IBA 01/2013
1	Fibronectins (Fibronectin)IBA 01/2013
1	Nucleosomes (Nucleosome)IBA 03/2012
1	Cathepsin DIBA 02/2012
1	Complement System Proteins (Complement)IBA 02/2012
1	MitogensIBA 03/2009
1	RNA (Ribonucleic Acid)IBA 07/2007
1	Plasminogen Activator Inhibitor 1IBA 07/2007
1	VitronectinIBA 12/2004
1	IntegrinsIBA 06/2003
1	adhesion receptorIBA 06/2003

Therapy/Procedure

1	Endarterectomy (Thromboendarterectomy) 01/2020
1	Ligation 01/2013
1	Percutaneous Coronary Intervention 01/2011
1	Liver Transplantation 03/2009